The value of eCOA in the era of digitally derived measures
As clinical research explores a broader range of digital measurement approaches, the value of eCOA continues to expand.
Historically, much of what clinical trials have revealed about patients’ health has come from research site visits, clinician assessments, and questionnaires completed by patients at regular intervals. These approaches remain an important foundation for clinical outcome assessment. However, for diseases that require long-term observation, change slowly, or fluctuate considerably in daily life, data collected only at scheduled visits may not fully capture patients’ everyday health.
Advances in wearable devices, mobile applications, sensors, and artificial intelligence are opening up more diverse approaches to measurement in clinical research. In addition to assessments at specific time points, researchers can collect health-related data continuously or repeatedly during patients’ daily lives and derive clinically meaningful measures from those data.
In August 2026, the FDA published Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations, outlining key considerations for the development and use of digitally derived measures (DDMs) in clinical research.
The paper explicitly states that DDMs may be used as clinical outcome assessments (COAs), biomarkers, or as part of multicomponent endpoints derived from multimodal data. This suggests that digitally derived measures can do more than support data collection and analysis: they may also contribute to clinical outcome assessment, offering researchers new sources of information about patients’ health and how it changes.
This trend is closely connected with the development of electronic clinical outcome assessment (eCOA). eCOA uses electronic devices to administer and manage clinical outcome assessments, including patient reports, clinician assessments, and observer reports. As wearable devices, mobile applications, and other digital health technologies evolve, eCOA has opportunities to work alongside them, allowing patients’ reported experiences to complement other digital measurements.
1. From collecting data to measuring health: what changes with DDMs?
DDMs are measures derived through processing data collected using digital health technologies (DHTs). These technologies can include wearable devices, mobile applications, and sensors.
For example, wearable devices can record activity levels or movement patterns, while mobile devices can support specific cognitive or motor tasks. With appropriate processing and validation, these data may yield measures that describe patients’ functioning or health.
The FDA paper specifically identifies COAs as one potential use of DDMs. COAs focus on patients’ symptoms, functioning, or other clinical outcomes, and digital measurement may provide new sources of information for assessing those outcomes. In suitable studies, for example, device-collected activity data may supplement patients’ reports of their ability to carry out daily activities, helping researchers understand their health from different perspectives.
Digital data do not automatically become valid clinical outcome measures. Each measure still needs to be assessed in light of its intended use, target population, measurement methods, and supporting validation evidence. The value of digital technology lies not only in collecting more data, but in whether those data can answer a clearly defined clinical question.
The shift represented by DDMs therefore extends beyond updating data collection tools. It also involves further exploration of how, how often, and in what settings clinical research measures health.
2. The value of eCOA is expanding as DDMs develop
eCOA encompasses tools and methods for administering and managing clinical outcome assessments electronically, including patient-reported outcomes (PROs), clinician-reported outcomes (ClinROs), observer-reported outcomes (ObsROs), and certain task-based performance outcomes (PerfOs).
The FDA’s connection between DDMs and COAs provides a useful starting point for understanding the role of digital measurement in clinical outcome assessment. For eCOA, this trend does not mean that device data will replace conventional questionnaire-based assessments. Instead, it suggests that clinical research can explore how different assessment approaches complement one another, guided by clearly defined study objectives.
1. Connecting patient experience with other digital measurements
Patient reports capture patients’ subjective experiences of symptoms, functioning, and quality of life. DHTs such as wearable devices may offer information about other dimensions, including activity levels and movement patterns.
For example, patients in a clinical study may use eCOA to report difficulties with daily activities, while a wearable device records their activity over a period of time. These two sources can describe patients’ health from different perspectives, giving researchers a broader basis for assessment.
The two types of data are not directly interchangeable. A change in device-recorded activity does not necessarily indicate clinical benefit, and patient reports may differ from device data. Interpreting these differences requires consideration of the disease, study protocol, and suitability of the measurement instruments.
2. Extending assessment beyond individual time points to observe change
eCOA can support regular or repeated electronic assessments according to the study protocol. With an appropriate study design, it can also work alongside technologies such as wearable devices, helping researchers combine patient reports and digital measurements to observe changes in health over different timescales.
For studies that require long-term observation of changes in symptoms, functioning, or daily activities, this collaboration may supplement the information available from a single assessment time point. Whether the additional data improve assessment quality still depends on appropriate validation of the measurement methods and on whether the data help answer the research question.
3. Supporting digital clinical outcome assessment
When clinical research explores DDMs and other digital measurement approaches, it needs clearly defined measurement objectives, data collection and processing methods, data quality requirements, and an understanding of how the results will be interpreted clinically.
eCOA can provide electronic administration and management of clinical outcome assessments, supporting the completion of questionnaires, diaries, and related assessment tasks according to the protocol. Studies that combine eCOA with other DHTs should also define the purpose of each data source, how data will flow between systems, and the quality controls required.
EClinCloud: aligning electronic assessments with clinical research needs
EClinCloud continues to follow the use of clinical outcome assessments across different disease areas and provides electronic assessment support through eCOA, covering ePRO, ClinRO, ObsRO, PerfO, and other types of clinical outcome assessment. In studies with demanding cognitive, behavioral, and functional assessments, electronic assessment involves more than moving a paper questionnaire onto a digital device. It also encompasses electronic instrument administration, assessment workflow design, rater training, patient experience, and data quality management to improve consistency in assessment and the usability of the resulting data.
As research draws on multiple data sources, EClinCloud also follows and supports the combined use of eCOA and other digital measurement approaches. It explores connections and integration between data sources to support the combined analysis of patient-reported outcomes, clinical assessment data, and device-collected data.
Michael Qin, PhD, founder of EClinCloud, said:
“Digital technology is expanding the ways clinical research can observe patients’ health, but technology itself is not the goal. Our focus is on bringing patient experience, clinical assessment, and digital measurement together around real clinical needs, and on using sound study design and quality management to help data better serve clinical research.”
The development of DDMs is opening up new possibilities for measurement in clinical research, and eCOA will remain an important part of that landscape. As technology, clinical evidence, and research experience continue to develop, electronic assessments may work alongside a broader range of digital measurement approaches to provide researchers with richer information about patients.
